Navigation Links
Proacta Incorporated and Yakult Honsha Announce Expansion of Their Collaborative Research, Development and Commercialization Agreement
Date:8/3/2011

SAN DIEGO, Aug. 3, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo: 2267) today announced the expansion of their Collaborative Research, Development and Commercialization Agreement to also include Proacta's PR610 compound, a hypoxia-activated pro-drug for the treatment of cancer.  Based on compelling pre-clinical data on PR610, the parties agreed to expand their existing collaboration to include PR610.  The initial agreement, signed in February 2011, for Proacta's hypoxia-activated pro-drug, PR509, granted Yakult research, development and commercialization rights to PR509 in Japan.

(Logo:  http://photos.prnewswire.com/prnh/20110803/LA45514LOGO)

(Logo:  http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-b)

"Based on recent pre-clinical study results, we believe that PR610 could perform very well in the clinic," said John C. Gutheil, MD, Proacta's CEO. "We have developed a strong relationship with Yakult in the short time that we have been working together. We are delighted that Yakult is interested in PR610 and that they share our optimism regarding the potential of this molecule."

Mr. Shigeyoshi Sakamoto, Head, Pharmaceutical Division/ Managing Executive Officer, Member of the Board of Yakult, said, "We are pleased to have the opportunity to expand our collaborative research, development, and commercialization agreement with Proacta to include PR610. This molecule has shown unique promise and provides Yakult with an option on two promising molecules within Proacta's hypoxia-activated irreversible multi-kinase inhibitors portfolio for the treatment of cancer. We look forward to the continued progress and advancement of the program so that we can more quickly bring promising new treatments to patients suffering from cancer."

About PR509 and PR610

PR509 and PR610 are Proacta's proprietary hypoxia-activated irreversible multi-kinase inhibitors discovered at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand.  Reversible multi-kinase inhibitors (MKI) are currently in use for the treatment of several types of cancer.  However, resistance often develops to reversible MKI's.  In addition, reversible MKI's have side effects that limit their use at higher doses.  Both PR509 and PR610 utilize an irreversible MKI that is activated only in areas of severe hypoxia, a characteristic of most solid tumors.  Localized release of the irreversible MKI leads to higher concentrations in the tumor relative to normal tissues, which should result in improved efficacy and fewer side effects.  In addition, irreversible MKI inhibitors are not effected by some of the resistance mechanisms that limit use of reversible MKI inhibitors.

Clinical Development Status

PR509 and PR610 are currently targeted for development in non-small cell lung cancer resistant to reversible tyrosine kinase inhibitors such as erlotinib and /or gefitinib, where an effective treatment has yet to be established.  In addition to NSCLC, Proacta expects to evaluate the molecules in other cancers such as gastric, breast, and pancreatic that are currently treated with first-generation reversible tyrosine kinase inhibitors.

About Proacta Incorporated

Proacta is a San Diego based biotechnology company dedicated to the development and commercialization of hypoxia-activated oncology drugs. Proacta is currently conducting a phase II study of PR104, a hypoxia activated alkylator, in patients with relapsed or refractory leukemia.  In addition, Proacta has a pipeline of hypoxia-activated prodrugs for the treatment of cancer that are licensed from the University of Auckland in New Zealand.  For more information on Proacta, visit the Proacta web site at www.proacta.com.

About Yakult

Yakult is a leading Japanese company focused on the development and marketing of pharmaceuticals, foods, beverages, and cosmetics. With respect to its pharmaceutical business, Yakult has an emerging presence in oncology. For more information on Yakult, visit: http://www.yakult.co.jp/english/index.html or view the following company profile:

http://www.yakult.co.jp/english/pdf/profile2010-2011.pdf


'/>"/>
SOURCE Proacta Incorporated; Yakult Honsha Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Proacta Incorporated and Yakult Honsha Announce an Agreement for the Collaborative Research, Development and Commercialization for Proactas PR509 Compound
2. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
3. Genta Incorporated Announces Third Quarter 2007 Financial Results
4. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
5. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
6. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
7. Mars, Incorporated Commits Over $2 Million to Federal Agency for Human-Animal Interaction Research
8. Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2010
9. Accuray Incorporated to Present at 20th Annual Oppenheimer Healthcare Conference
10. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
11. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017 Precision medicine is an emerging ... of disease. The approach allows doctors and physicians ... The approach studies the individual profile at a ... In January 2015, Precision Medicine Initiative (PMI) was ... with more than one million volunteers. All of ...
(Date:1/17/2017)... Pa. , Jan. 17, 2017 Secretary ... and Alcohol Programs Secretary Gary Tennis are ... carfentanil, following two recent overdose deaths from the drug ... "Carfentanil is intended to sedate large animals and ... kill anyone who comes into contact with it," Secretary ...
(Date:1/17/2017)... YORK , Jan. 17, 2017 EU5 ... GlobalData,s new report, "EU5 Glucose Monitoring Market Outlook ... Glucose Monitoring market. The report provides value, in millions ... (USD) within market segments - Blood Glucose Meters, Blood ... provides company shares and distribution shares data for each ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... , ... January is National Stalking Awareness Month (NSAM), now in its fourteenth year, ... commit the crime of stalking, a very real danger to many in our community. ... stalking and other crimes. , “Stalking: know it. Name it. Stop it.”—so reads the theme ...
(Date:1/17/2017)... ... 17, 2017 , ... For breast cancer clinicians and researchers who were unable ... a more intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the ... by Imedex on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of the original ... featuring DRTV campaigns regarding the topic of Beauty and Personal Care. ... themselves. What better way to commit to these changes than beginning with personal care ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting ... Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted ... providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug ...
(Date:1/17/2017)... ... 17, 2017 , ... A prescription medication bottle, pocket knife, luggage and a ... Cradle Product Design Challenge , the Cradle to Cradle Products Innovation Institute ... challenges scheduled to run through early 2018. The challenges are presented by the Institute ...
Breaking Medicine News(10 mins):